These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11821624)

  • 21. Heart failure, platelet activation and inhibition of the renin-angiotensin-aldosterone system.
    Bauersachs J; Schäfer A
    Arch Mal Coeur Vaiss; 2004 Sep; 97(9):889-93. PubMed ID: 15521482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone biosynthesis, regulation, and classical mechanism of action.
    Williams GH
    Heart Fail Rev; 2005 Jan; 10(1):7-13. PubMed ID: 15947886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production.
    Thai HM; Do BQ; Tran TD; Gaballa MA; Goldman S
    J Card Fail; 2006 Apr; 12(3):240-5. PubMed ID: 16624690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid non-genomic effects of aldosterone on rodent vascular function.
    Uhrenholt TR; Schjerning J; Rasmussen LE; Hansen PB; Nørregaard R; Jensen BL; Skøtt O
    Acta Physiol Scand; 2004 Aug; 181(4):415-9. PubMed ID: 15283753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of aldosterone and MR blockade on the brain and the kidney.
    Stier CT; Rocha R; Chander PN
    Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke).
    Laragh JH
    J Hum Hypertens; 1995 Jun; 9(6):385-90. PubMed ID: 7473515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity.
    Pérez-Rojas JM; Derive S; Blanco JA; Cruz C; Martínez de la Maza L; Gamba G; Bobadilla NA
    Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1020-30. PubMed ID: 15998842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
    Struthers AD; MacDonald TM
    Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome and endothelial dysfunction.
    Fornoni A; Raij L
    Curr Hypertens Rep; 2005 Apr; 7(2):88-95. PubMed ID: 15748531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 34. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
    Pasquale PD; Stefano GD; Paterna S
    Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation.
    Liu SL; Schmuck S; Chorazcyzewski JZ; Gros R; Feldman RD
    Circulation; 2003 Nov; 108(19):2400-6. PubMed ID: 14557368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone's mechanism of action: roles of lysine-specific demethylase 1, caveolin and striatin.
    Baudrand R; Pojoga LH; Romero JR; Williams GH
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):32-7. PubMed ID: 24275769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldosterone: a risk factor for vascular disease.
    Fritsch Neves M; Schiffrin EL
    Curr Hypertens Rep; 2003 Feb; 5(1):59-65. PubMed ID: 12530937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological modulations of the renin-angiotensin-aldosterone system in human congestive heart failure: effects on peripheral vascular endothelial function.
    Nakamura M
    Curr Vasc Pharmacol; 2004 Jan; 2(1):65-70. PubMed ID: 15320834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of aldosterone antagonist therapy].
    Christ M; Grimm W; Maisch B
    Internist (Berl); 2004 Mar; 45(3):347-54. PubMed ID: 14997312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.